Creation and implementation of a historical controls database from randomized clinical trials

Journal of the American Medical Informatics Association

Volumn 20, Issue E1, 2013, Pages

  Desai, Jigar R ^a   Bowen, Edward A ^a   Danielson, Mark M ^a   Allam, Rajasekhar R ^a   Cantor, Michael N ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ARTICLE; CONTROL SYSTEM; DATA BASE; DRUG PROGRAM; HUMAN; INFORMATION CENTER; INFORMATION PROCESSING; MEDICAL INFORMATICS; PARALLEL DESIGN; PATIENT CODING; PILOT STUDY; POPULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD; CONTROL GROUP; DOCUMENTATION; EPLACEBO; EPLACEBO DATABASE; HISTORICAL CONTROLS DATABASE; METHODOLOGY;

EPLACEBO; EPLACEBO DATABASE; HISTORICAL CONTROLS DATABASE;

ABSTRACTING AND INDEXING AS TOPIC; CONTROL GROUPS; DATABASES AS TOPIC; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

MLCS; MLOWN;

EID: 84881357460     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2012-001257     Document Type: Article

References (35)

1. Miller RG, Moore DH, Forshew DA, et al. Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis. Neurology 2011;77:973-9.
2. Polman CH, Reingold SC, Barkhoff F, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2008;70:1134-40.
3. Fleischhacker WW, Czobor P, Hummer M, et al. Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 2003;60:458-64.
4. Splawinski J, Kuzniar J. Clinical trials: active control vs placebo-what is ethical? Sci Eng Ethics 2004;10:73-9.
5. Gupta S, Fugh-Berman AJ, Scialli A. Ethics and eplerenone considerations. J Med Ethics 2013;39:110-4.
6. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med 1994;331:394-8.
7. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. II. Practical issues and specific cases. Ann Intern Med 2000;133:464-70.
8. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011;364:476-80.
9. Emanuel EJ, Miller FG. The ethics of placebo-controlled trials-a middle ground. N Engl J Med 2001;345:915-19.
10. French JA, Wang S, Warnock B, et al. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010;51:1936-43.
11. French JA, Temkin NR, Shneker BF. Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapuetics 2012;9:176-84.
12. Berlin JA, Colditz GA. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA 1999;281:830-4.
13. Klein NP, Hansen J, Lewis E, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010;29:613-17.
14. Wagner JA, Wright EC, Enni MM. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors. Clin Pharmacol Ther 2009;86:619-25.
15. Tan SB, Machin D, Tai BC, et al. A Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer. Br J Cancer 2002;86:843-50.
16. Gaba RC, Ansari SA, Roy SS, et al. Embolization of intracranial aneurysms with hydrogel-coated coils versus inert platinum coils: effects on packing density, coil length and quantity, procedure performance, cost, length of hospital stay, and durability of therapy. Stroke 2006;37:1443-50.
17. Watts NB, Brown JP, Cline G. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1 year compared with historical placebo. J Clin Densitom 2010;13:56-62.
18. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA 1999;281:841-4.
19. Hammad TA, Pinheiro SP, Neyarapally GA. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials 2011;8:559-70.
20. Baker SG, Linderman KS. Rethinking historical controls. Biostatistics 2002;2:383-96.
21. Zhang S, Cao J, Ahn C. Calculating sample size in trials using historical controls. Clin Trials 2010;7:343-52.
22. Xiong X, Tan M, Bovett J. A sequential procedure for monitoring clinical trials against historical controls. Stat Med 2007;26:1497-511.
23. Neuenschwander B, Capkun-Niggli G, Branson M, et al. Summarizing historical information on controls in clinical trials. Clin Trials 2010;7:5-18.
24. U.S. Food and Drug Administration. FDA/CDER Guidance for the use of Bayesian statistics in medical device clinical trials - Draft guidance for industry and FDA staff. 2006.
25. Oracle® Clinical. http://www.oracle.com/us/industries/life-sciences/046720.html (accessed Apr 2012).
26. SAS®. http://www.sas.com/ (accessed Apr 2012).
27. TOAD®. http://www.quest.com/toad-for-oracle/ (accessed Apr 2012).
28. Tibco® Spotfire®. http://spotfire.tibco.com/products/spotfire-professional/exploratory-data-analysis.aspx (accessed Apr 2012).
29. Kuchinke W, Aerts J, Semler SC, et al. CDISC standard-based electronic archiving of clinical trials. Methods Inf Med 2009;48:408-13.
30. Tatonetti NP, Ye PP, Daneshjou R, et al. Data-driven prediction of drug effects and interactions. Sci Transl Med 2012;4:125-31.
31. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 2009;18:427-36.
32. Juilous SA, Mulle MA. Confounding and the Simpson's paradox. BMJ 1994;309:1480-1.
33. U.S. Food and Drug Administration. FDA/CDER Guidance for Industry: adaptive Design Clinical Trials for Drugs and Biologics. February 2010.
34. U.S. Food and Drug Administration. FDA Driving Biomedical Innovation: Initiatives to Improve Products for Patients. October 2011.
35. Critical Path Institute. http://c-path.org (accessed Jul 2012).